Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

R&D Systems™ GSK 329
SDP

Catalog No. RD10195098 Shop All Novus Products
Change view
Click to view available options
Quantity:
10 mg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
RD10195098 10 mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. RD10195098 Supplier R&D Systems™ Supplier No. 7637/10

Customers require a valid business account associated to their profile to access pricing and ordering options.

missing translation for 'validMainframeMsg'

A Tocris product, part of R&D Systems. Potent and selective TNNI3K inhibitor, orally bioavailable

GSK 329 is a potent and selective TNNI3K (cardiac troponin I-interacting kinase) inhibitor (IC50 = 10 nM). It exhibits selectivity for TNNI3K over human VEGFR2 (40-fold), p38α (80-fold), B-Raf (>200-fold) and displays >100-fold selectivity over 80% of 185 kinases tested. In vivo, GSK 329 reduces infarct size, ROS levels, and p38 activation in a mouse model of ischemia/reperfusion cardiac injury. This compound is orally bioavailable.

Specifications

Chemical Name or Material N-[3,5-Dichloro-4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]-N'-[3-(trifluoromethyl)phenyl]urea
CAS 1268490-12-5
Quantity 10 mg
Product Line Tocris
Target MAPK Inhibitors
Molecular Formula C19H14Cl2F3N5O2
Purity 0.98
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.